Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2016-04-22 | James A. Schoeneck, age 58, has served on our board of directors since April 2010. ... Our compensation committee consists of Messrs. Schoeneck, Kearns and Stern and Drs. Rosenkranz and Routti. ... Our audit committee consists of Messrs. Riggs, Edwards, Henderson, Schoeneck, and Stern and Dr. Kurkijärvi. ... Our nominating and corporate governance committee consists of Messrs. Kearns and Riggs and Drs. Rosenkranz and Tamura. ... The following table sets forth information regarding non-cash compensation earned by or paid to our non-employee directors during 2015: James A. Schoeneck $190,966. |
| 2017-04-24 | James A. Schoeneck, age 59, has served on our board of directors since April 2010. He serves on Audit, Compensation (Chair), and Nominating and Corporate Governance committees. Director compensation in 2016 was $202,965. |
| 2018-04-24 | James A. Schoeneck, age 60, has served on our board of directors since April 2010. ... Mr. Schoeneck was Chief Executive Officer of Depomed, Inc., a commercial specialty pharmaceutical company, from 2011 until 2017, and joined the Board of Depomed in 2007. ... Our board of directors has determined that ... Mr. Schoeneck ... comprise our audit committee, compensation committee ... |
| 2019-04-23 | James A. Schoeneck, age 61, has served on our board of directors since April 2010... The audit committee consists of Messrs. Edwards and Schoeneck and Dr. Kurkijärvi... The compensation committee consists of Messrs. Kearns, Lema, Riggs, and Schoeneck and Dr. Routti... The nominating and corporate governance committee consists of Messrs. Henderson, Kearns, and Riggs and Drs. Rosenkranz and Tamura... The following table sets forth information regarding compensation earned by or paid to our non-employee directors during 2018: James A. Schoeneck: $475,878. |
| 2020-04-23 | James A. Schoeneck, age 62, was appointed Chairperson of our Board of Directors in January 2020 and has served on our board of directors since April 2010. ... Mr. Schoeneck was Chair of the compensation committee and a member of the audit committee prior to the start of 2019 until August 26, 2019. |
| 2021-04-13 | James A. Schoeneck, age 63, was appointed Chairperson of our Board of Directors in January 2020 and has served on our board of directors since April 2010. Following the unexpected passing of Thomas B. Neff, FibroGen’s Founder and Chief Executive Officer, Mr. Schoeneck served as Interim Chief Executive Officer from August 2019 until January 2020. ... Our non-employee directors are paid annual cash compensation of $50,000 each and our non-executive Chairperson is paid annual cash compensation of $100,000. ... The following table sets forth information regarding compensation earned by or paid to our non-employee directors during fiscal year 2020: ... James A. Schoeneck, Chairperson (4) Fees Earned or Paid in Cash: $147,554, Stock Option Awards: $148,442, RSU Awards: $153,643, Total: $449,639. |
| 2022-04-29 | James A. Schoeneck, age 64, was appointed Chairperson of the Board in January 2020... Total compensation in 2021 was $337,072. |
| 2023-04-27 | James A. Schoeneck, age 65, was appointed Chairperson of the Board in January 2020 and has served on the Board since April 2010. ... The Board appointed Mr. Schoeneck as Chairperson of the Board in January 2020. ... The following table sets forth information regarding compensation earned by or paid to our non-employee directors during fiscal year 2022: ... James A. Schoeneck, Chairperson $437,839 ... |
| 2024-04-24 | James A. Schoeneck, age 66, was appointed Chairperson of our Board of Directors in January 2020 and has served on our board of directors since April 2010. The following table provides membership and meeting information for the year ended December 31, 2023 for each of the Board committees: James A. Schoeneck, Chairperson - Audit Committee, Compensation Committee Chair, Nominating and Corporate Governance Committee member. Director compensation table shows total $499,576. |
Data sourced from SEC filings. Last updated: 2026-02-03